Literature DB >> 32869270

High-intensity exercise improves pulmonary function and exercise tolerance in a patient with TSC-LAM.

Thomas William Lowder1.   

Abstract

INTRODUCTION: While exercise has been shown to improve respiratory symptoms, exercise tolerance, and bone mineral density in many populations, no supervised exercise training interventions have been undertaken in patients with lymphangioleiomyo-matosis (LAM).
MATERIAL AND METHODS: One patient with TSC-LAM (tuberous sclerosis complex lymphangioleiomyomatosis) participated in two weekly sessions (50-60 min) of supervised aerobic exercise at 80-85% heart rate max for one year. Treadmill ergometry (VO2peak), spirometry (FEV1, FVC, FEV1/FVC, peak flow), and bone mineral density testing were performed prior to every 3 months.
RESULTS: After one year of supervised aerobic exercise training we saw dramatic increases in the patient's VO2max (20%), FEV1 (9.5%), FEV1/FVC (9.1%) and peak flow (47%).
CONCLUSIONS: The results from this study indicate that supervised exercise training can improve exercise tolerance and pulmonary function in a patient with lymphangioleiomyomatosis. Further research is needed, including longitudinal studies with larger sample sizes, to determine long-term effects and consistency of these findings. Aerobic exercise may offer a viable alternative or com-pliment to pharmacological interventions in the treatment of lymphangioleiomyomatosis. We show that high-intensity exercise training can markedly and safely improve pulmonary function in a patient with TSC-LAM. While we did not record quality of life or mood states, our patient did report improved self-confidence as well as enhanced mood.

Entities:  

Keywords:  exercise; lymphangioleiomyomatosis; tuberous sclerosis

Mesh:

Year:  2020        PMID: 32869270     DOI: 10.5603/ARM.a2020.0129

Source DB:  PubMed          Journal:  Adv Respir Med        ISSN: 2451-4934


  1 in total

1.  Physiotherapy in lymphangioleiomyomatosis: a systematic review.

Authors:  Victoria Maria Garcia de Medeiros; Jéssica Gonçalves de Lima; Claudia Rosa; Juliana Rega; Mauro Felippe Felix Mediano; Luiz Fernando Rodrigues Junior
Journal:  Ann Med       Date:  2022-12       Impact factor: 5.348

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.